⚕ GalenOps CRO console
← SITE003 (CAN)

SITE003-0384

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE003 (CAN) (Dr. Okafor) · consented 2023-05-23
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-29 (study day 17); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Fatigue — outcome: UNKNOWN; onset 2023-07-07 (study day 25); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-04 (study day 114); relationship: Y

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-10-13 (study day 123); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-11-19 (study day 160); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 187); relationship: not assessed; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-02-05 (study day 238); relationship: N

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 292); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.